Structure-based design of selective inhibitors of dihydrofolate reductase: Synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4853-4860

  Rosowsky, Andre ^a   Cody, Vivian ^b   Galitsky, Nikolai ^b   Fu, Hongning ^a   Papoulis, Andrew T ^a   Queener, Sherry F ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDINE DERIVATIVE; AZEPINE DERIVATIVE; CARBAZOLE DERIVATIVE; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIPHENYLAMINE; PHENOTHIAZINE; PHENOXAZINE DERIVATIVE; PTERIDINE DERIVATIVE; TRIMETHOPRIM; TRIMETREXATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; MYCOBACTERIUM AVIUM; NONHUMAN; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

ANIMALS; ANTIPARASITIC AGENTS; AZEPINES; DRUG DESIGN; FOLIC ACID ANTAGONISTS; HUMANS; LIVER; MODELS, MOLECULAR; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS; PTERIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROFOLATE DEHYDROGENASE; TOXOPLASMA;

EID: 0032743720     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990331q     Document Type: Article

References (56)

1. (a) Falloon, J.; Masur, H. Infectious complications of HIV. In AIDS Etiology, Diagnosis, Treatment and Prevention, 3rd ed.; DeVita, V. T., Hellman, S., Rosenberg, S. A., Eds.; Lippincott: Philadelphia, 1992.
2. (b) Klepser, M. E.; Klepser, T. B. Drug treatment of HIV-related opportunistic infections. Drugs 1997, 53, 40-73.
3. DeClercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-1517.
4. (a) Queener, S. F. New drug developments for opportunistic infections in immune-compromised patients: Pneumocystis carinii. J. Med. Chem. 1995, 38, 4739-4759.
5. (b) Gangjee, A.; Elzein, E.; Kothare, M.; Vasudevan, A. Classical and nonclassical antifolates as potential antipneumocystis and antitoxoplasma agents. Curr. Pharm. Des. 1996, 2, 263-280.
6. (a) Allegra, C. J.; Chabner, B. A.; Tuazon, C. U.; Ogata-Arakaki, D.; Baird, B.; Drake, J. C.; Simmons, J. T.; Lack, E. E.; Shelhamer, J. H.; Balls, F.; Walker, R.; Kovacs, J. A.; Lane, H. C.; Masur. H. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1987, 317, 978-985.
7. (b) Sattler, F. R.; Frame, P.; Davis, R.; Nichols, L.; Shelton, B.; Akil, B.; Baughman, R.; Hughlett, C.; Weiss, W.; Boylen, C. T.; van der Horst, C.; Black, J.; Powderly, W.; Steigbigel, R. T.; Leedom, J. M.; Masur, H.; Feinberg, J.; Benoit, S.; Eyste, E.; Gocke, D.; Beck, K.; Lederman, M.; Phari, J.; Reichman, R.; Sacks, H. S.; Soiero, R. Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS - a prospective controlled multicenter investigation of the AIDS clinical trials group Protocol 029/031. J. Infect. Dis. 1994, 170, 165-172.
8. Falloon, J.; Allegra, C. J.; Kovacs, J.; O'Neill, D.; Ogata-Arakaki, D.; Feuerstein, I.; Polis, M.; Davey, R.; Lane, H. C.; LaFon, S.; Rogers, M.; Zunich, K.; Turlo, J.; Tuazon, C.; Parenti, D.; Simon, G.; Masur, H. Piritrexim with leucovorin for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Clin. Res. 1990, 38, 361A.
9. (a) Fischl, M. A.; Dickinson, G. M.; La Voie, L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. J. Am. Med. Assoc. 1988, 105, 45-48.
10. (b) Medina, I.; Mills, J.; Leoung, G.; Hopewell, P. C.; Modin, G.; Benowitz, N.; Wofsy, C. B. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N. Engl. J. Med. 1990, 323, 776-782.
11. (c) Podzamczer, D.; Salazar, A.; Jimenes, J.; Santin, M.; Consiglio, E.; Casanova, A.; Rufi, G.; Gudiol, F. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV. Ann. Intern. Med. 1995, 122, 755-761.
12. (a) Caumes, E.; Roudier, C.; Rogeaux, O.; Bricaire, F.; Gentilini, M. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole associated Pneumocystis carinii pneumonia. Clin. Infect. Dis. 1994, 17, 319-323.
13. (b) Roudier, C.; Caumes, E.; Rogeauz, O.; Bricaire, F.; Gentilini, M. Adverse cutaneous reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Arch. Dermatol. 1994, 30, 1383-1386.
14. (a) Gangjee, A.; Devraj, R.; Queener, S. F. Synthesis and dihydrofolate reductase activities of 2,4-diamino-5-deaza and 2,4-diamino-5,10-dideaza lipophilic antifolates. J. Med. Chem. 1997, 40, 470-478. [For earlier papers from this group in this area, see ref 3a; for recent papers from other groups, see refs 9 and 10.]
15. (b) Gangjee, A.; Vasudevan, A.; Queener, S. F. Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. J. Med. Chem. 1997, 40, 479-485.
16. 9-methylation and bridge atom variation on the activity of 5-substituted 2,4-diaminopyrrolo[2,3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1997, 40, 1173-1177.
17. (d) Gangjee, A.; Shi, J.; Queener, S. F. Synthesis and biological activities of conformationally restricted, tricyclic nonclassical antifolates as inhibitors of dihydrofolate reductases. J. Med. Chem. 1997, 40, 1930-1936.
18. (e) Gangjee, A.; Vasudevan, A.; Queener, S. F. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem. 1997, 40, 3032-3039.
19. (a) Piper, J. R.; Johnson, C. A.; Krauth, C. A.; Carter, R. L.; Hosmer, C. A.; Queener, S. F.; Borotz, S. E.; Pfefferkorn, E. R. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and Pneumocystis carinii in in vitro evaluations. J. Med. Chem. 1996, 39, 1271-1280.
20. (b) Jackson, H. C.; Biggadike, K.; McKillingin, E.; Kinsman, O. S.; Queener, S. F.; Lane, A.; Smith, J. E. 6,7-Disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. Antimcirob. Agents Chemother. 1996, 40, 1371-1374.
21. (c) Robson, C.; Meek, M. A.; Grundwaldt, J.-D.; Lambert, P. A.; Queener, S. F.; Schmidt, D.; Griffin, R. J. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents. J. Med. Chem. 1997, 40, 3040-3048.
22. (a) Rosowsky, A.; Mota, C. E.; Queener, S. F. Brominated trimetrexate analogues as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Heterocycl. Chem. 1996, 33, 1959-1966. [For earlier papers from this group in this area, see ref 3a.]
23. (b) Rosowsky, A.; Papoulis, A. T.; Queener, S. F. 2,4-Diaminothieno[2,3-d]pyrimidine lipophilic antifolates as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1997, 40, 3694-3699.
24. (c) Rosowsky, A.; Forsch, R. A.; Queener, S. F. Synthesis of 2,4-diaminopteridines with bulky lipophilic groups at the 6-position as inhibitors of Pneumocystis carinii, Toxoplasma gondii, and mammalian dihydrofolate reductase. Pteridines 1997, 8, 173-187.
25. (d) Rosowsky, A.; Papoulis, A. T.; Queener, S. F. 2,4-Diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine analogues of trimethoprim as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J. Med. Chem. 1998, 41, 913-918.
26. (e) Rosowsky, A.; Papoulis, A. T.; Forsch, R. A.; Queener, S. F. Synthesis and antiparasitic and antitumor activity of 2,4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. J. Med. Chem. 1999, 42, 1007-1017.
27. (f) Rosowsky, A.; Papoulis, A. T.; Queener, S. F. One-step synthesis of novel 2,4-diaminopyrimidine antifolates from bridged alicyclic ketones and cyanoguanidine. J.Heterocycl. Chem. 1999, 36, 723-728.
28. (a) Edman, J. C.; Edman, U.; Cao, M.; Lundgren, B.; Kovacs, J. A.; Santi, D. V. Isolation and expression of the Pneumocystis carinii dihydrofolate reductase gene. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8625-8629.
29. (b) Sirawaraporn, W.; Edman, J. C.; Santi, D. V. Purification and properties of recombinant Pneumocystis carinii dihydrofolate reductase. Protein Express. Purif. 1991, 2, 313-316.
30. (c) Delves, C. J.; Ballantine, C. P.; Tansik, R. L.; Baccanari, D. P. Stammers, D. K. Refolding of recombinant Pneumocystis carinii dihydrofolate reductase and characterization of the enzyme. Protein Express. Purif. 1993, 4, 16-23.
31. (d) Margosiak, S. A.; Appleman, J. R.; Santi, D. V. Blakley, R. L. Dihydrofolate reductase from the pathogenic fungus Pneumocystis carinii: catalytic properties and interaction with antifolates. Arch. Biochem. Biophys. 1993, 305, 499-508.
32. (a) Champness, J. N.; Achari, A.; Ballantine, S. P.; Bryant, P. K.; Delves, C. J.; Stammers, D. K. The structure of Pneumocystis carinii dihydrofolate reductase to 1.9 A resolution. Structure 1994, 2, 915-924.
33. (b) Cody, V.; Galitsky, N.; Luft, J. R.; Pangborn, W.; Gangjee, A.; Devraj, R.; Queener, S. F.; Blakley, R. L. Comparison of ternary complexes of Pneumocystis carinii and wild-type human dihydrofolate reductase with a novel classical antitumor furo[2,3-d]pyrimidine antifolate. Acta Crystallogr. D 1997, D53, 638-649.
34. +. Biochemistry 1999, 38, 4304-4312.
35. (a) Southerland, W. M. A molecular model of the folate binding site of Pneumocystis carinii dihydrofolate reductase. J. Comput.-Aided Mol. Des. 1994, 8, 113-122.
36. (b) Geschwend, D. A.; Good, A. C.; Kuntz, I. D. Molecular docking towards drug discovery. J. Mol. Recognit. 1996, 9, 175-186.
37. (c) Geschwend, D. A.; Sirawaraporn, W.; Santi, D. V.; Kuntz, I. D. Specificity in structure-based design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. Proteins 1997, 29, 59-67.
38. (a) Gangjee, A.; Guo, X.; Queener, S. F.; Cody, V.; Galitsky, N.; Luft, J. R.; Pangborn, W. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d]pyrimidines. J. Med. Chem. 1998, 44, 1263-1271.
39. (b) Gangjee, A.; Elzein, E.; Queener, S. F.; McGuire, J. J. Synthesis and biological activities of tricyclic conformationally restricted tetrahydropyrido annulated furo[2,3-d]pyrimidines as inhibitors of dihydrofolate reductases. J. Med. Chem. 1998, 41, 1409-1416.
40. (c) Gangjee, A.; Vidwans, A. P.; Vasudevan, A.; Queener, S. F.; Kisliuk, R. L.; Cody, V.; Li, R.; Galitsky, N.; Luft, J. R.; Pangborn, W. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents. J. Med. Chem. 1998, 41, 3426-3434.
41. Piper, J. R.; Montgomery, J. A. Preparation of 6-(bromomethyl)-2,4-pteridinediamine hydrobromide and its use in improved syntheses of methotrexate and related compounds. J. Org. Chem. 1977, 42, 208-210.
42. (a) Broughton, M. C.; Queener, S. F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother. 1991, 35, 1348-1355.
43. (b) Chio, L.-C.; Queener, S. F. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob. Agents Chemother. 1993, 37, 1914-1923.
44. (a) Queener, S. F.; Bartlett, M. S.; Jay, M. A.; Durkin, M. M.; Smith, J. W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob. Agents Chemother. 1987, 31, 1323-1327.
45. (b) Kovacs, J. A.; Allegra, C. J.; Kennedy, S.; Swan, J. C.; Drake, J.; Parrillo, J. E.; Chabner, B.; Masur, H. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am. J. Trop. Med. Hyg. 1988, 39, 491-496.
46. (c) Baitlett, M. S.; Shaw, M.; Navaran, P.; Smith, J. W.; Queener, S. F. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob. Agents Chemother. 1995, 39, 2436-2441.
47. (a) Johnson, S. J.; Gupta, S. V.; Stevenson, K. J.; Freisheim, J. H. Purification and characterization of dihydrofolate reductase from Walker 256 carcinosarcoma. Can. J. Biochem. 1982, 60, 1132-1142.
48. (b) Delcamp, T. J.; Susten, S. S.; Blankenship, D. T.; Freisheim, J. H. Purification and characterization of dihydrofolate reductase from methotrexate-resistant human lymphoblastoid cells. Biochemistry 1983, 22, 633-639.
49. Burchall, J. J.; Hitchings, G. H. Inhibitor binding analysis of dihydrofolate reductases from various species. Mol. Pharmacol. 1965, 1, 126-136.
50. Shoen, C. M.; Choromanska, O.; Reynolds, R. C.; Piper, J. R.; Johnson, C. A.; Cynamon, M. H. In vitro activities of several diaminomethylpyridopyrimidines against Mycobacterium avium complex. Antimicrob. Agents Chemother. 1998, 42, 3315-3316.
51. Kovacs, J. A.; Allegra, C. J.; Beaver, J.; Boarman, D.; Lewis, M.; Parrilio, J. E.; Chabner, B.; Masur, H. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J. Infect. Dis. 1989, 160, 312-320.
52. Tripos, Inc., 1699 S. Handley Rd., Suite 303, St. Louis, MO 63144.
53. Rosowsky, A.; Queener, S. F.; Cody V. Inhibition of dihydrofolate reductases from Toxoplasma gondii, Pneumocystis carinii, and rat liver by rotationally restricted analogues of pyrimethamine and metoprine. Drug Des. Discovery 1999, 16, 25-40.
54. Evans, S. V. SETOR. J. Mol. Graph. 1993, 11, 148-153.
55. Tarnoky, A. L. Some properties of acridane and 2-chloro-7-methoxyacridane: their possible relationships to excretion product of mepacrine. Biochem. J. 1950, 46, 297-300.
56. Ohio, L.-C.; Boylard, L. A.; Nasr, M.; Queener, S. F. Identification of a class of sulfonamides highly active against dihydropteroate synthase from Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob. Agents Chemother. 1996, 40, 727-733.